Stroke Trial, Recruiting NCT03737786 Sponsor: University of California, Los Angeles Condition: Stroke
Back to Stroke

Stroke Trial, Recruiting

NCT03737786
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who had a stroke with a certain level of severity (measured by a standard stroke scale), assessed either within 16 hours or between 16 and 24 hours after they were last known to be well
  • People whose stroke is caused by a blockage in one of the major blood vessels supplying the front part of the brain
  • People whose brain scan results meet specific criteria showing how much of the brain has already been affected (the exact criteria depend on how much time has passed since the stroke)
  • People who were living independently or with only minor disability before the stroke (confirm with trial site)
  • People considered suitable for a procedure to physically remove the blood clot, where the procedure is expected to begin within 24 hours of last being known well and within 90 minutes of arriving at the emergency department

Who may not be able to join:

  • People who were placed on a breathing machine (ventilator) in the emergency department before being assessed by an anaesthetist, or for any reason other than the planned clot-removal procedure
  • People whose stroke symptoms improved quickly on their own, suggesting the blockage may have already cleared
  • People with a known serious allergy to the contrast dye used in medical imaging
  • People currently taking part in another clinical trial involving an investigational drug or medical device
  • People with significant kidney problems, as shown by specific blood test results
  • People who require kidney dialysis, or who cannot safely undergo a procedure involving dye injected into the blood vessels
  • People with a life expectancy of less than 90 days
  • People whose symptoms suggest bleeding around the brain (even if scans appear normal at first)
  • People with another serious illness or condition that could interfere with assessing how the brain or body recovers, or with completing follow-up visits
  • People with a recent history of illicit drug use, or who regularly drink more than 4 alcoholic drinks per day
  • People experiencing life-threatening low blood pressure due to severe infection or heart failure
  • People whose brain scan shows active bleeding inside the skull
  • People whose scan shows a large tumour or significant pressure/swelling in the brain (a very small, non-aggressive tumour type may not automatically exclude someone — confirm with trial site)
  • People whose scan shows that more than one-third of a major brain region is already affected by the stroke
  • People whose scan shows a large area of brain tissue already severely damaged
  • People whose scan shows the stroke is not in the front part of the brain
  • People whose imaging suggests, in the medical team's judgement, that the clot-removal procedure would not be appropriate or safe
  • People with a personal or family history of a serious reaction to general anaesthesia called malignant hyperthermia
  • People with a known allergic or severe reaction to anaesthetic medications
  • People who cannot lie flat on their back due to severe heart failure
  • People who depend on supplemental oxygen, or have a known lung condition (including pulmonary hypertension) that could make it difficult to come off a breathing machine after the procedure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Radoslav Raychev, MD, University of California, Los Angeles

Phone: 310-794-6379

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
28 November 2019
Est. completion
1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Modified Angiographic collateral circulation assessed by blinded core lab

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov